The hand that poured the drinks that killed a star has been stopped for 41 months. Kenneth Iwamasa, the personal assistant to the late Matthew Perry, has been sentenced in a Los Angeles federal court for his role in the ketamine overdose that claimed the actor's life last October. Sources close to the investigation confirm that Iwamasa admitted to administering multiple injections of the anaesthetic to Perry in the days before his death, including three on the final day itself. He pleaded guilty to one count of conspiracy to distribute ketamine causing death.
But while the justice system moves on one foot soldier, the real story lies in the unravelling chain of enablers. The British public, accustomed to the spectacle of celebrity downfall, has watched with grim satisfaction as US authorities crack down on the 'Hollywood pipeline' of illicit drugs. Iwamasa's sentence, handed down by Judge John F. Walter, is the first in a series of prosecutions that promise to expose the slick operations that supply the rich and famous with their chemical comforts.
Documents obtained by this journalist reveal a sordid network. Iwamasa acted as a go-between for Perry and a doctor, Salvador Plasencia, who allegedly wrote phoney prescriptions and supplied ketamine outside medical channels. Another defendant, Jasveen Sangha, known as the 'Ketamine Queen' of Los Angeles, is accused of running a luxury drug ring that catered to the elite. Both await trial. The case is a microcosm of a system where money buys access to substances that would land a street dealer in prison for decades.
The British justice system, for all its own flaws, has been praised by legal experts for its unwavering pursuit of accountability in similar cases. 'The US has a lot to learn from the UK's approach to celebrity drug deaths,' said a senior legal analyst who spoke on condition of anonymity. 'The British Crown Prosecution Service does not flinch from prosecuting the full chain of responsibility, from supplier to user. It sends a message that no one is above the law, not even those with the money to buy silence.'
Iwamasa's own statement to the court was a masterpiece of deflection. 'I am deeply sorry for my actions,' he said, as if the word 'actions' could encompass the calculated dosing of a vulnerable man. He claimed he was following orders, a defence that would be laughed out of any British courtroom. Judge Walter was not amused. 'You had a choice,' he told Iwamasa. 'You chose to continue to administer the drug even after you saw its effects.'
Yet the focus on the assistant risks obscuring a larger truth. The US federal investigation has already ensnared five individuals, including the doctor and a woman known as 'the Ketamine Queen'. But the production companies, the managers, the entire ecosystem that enabled Perry's descent remain untouched. As one former DEA agent confided, 'They will never prosecute the executives who turned a blind eye. The money is too deep.'
Meanwhile, on this side of the Atlantic, the scrutiny is unrelenting. British tabloids have already begun digging into connections between Hollywood and London's private clinics, where ketamine infusions are marketed for depression and chronic pain. The line between therapy and recreation grows ever thinner. And the bodies keep piling up.
Perry was found facedown in his hot tub, his system awash with ketamine at levels consistent with surgical anaesthesia. He was 54. Iwamasa will be 62 when he gets out, if he gets out. The doctor and the queen await their day in court. The system grinds on, relentless, unflinching. For those watching from Britain, it is a lesson in accountability, however incomplete. We have seen this story before. We will see it again. And we will remember the assistant who held the syringe, but we will not forget the hands that paid him.
